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Abstract: Vaccination remains the principal way to control seasonal infections and is the most effective
method of reducing influenza-associated morbidity and mortality. Since the 1940s, the main method
of producing influenza vaccines has been an egg-based production process. However, in the event of
a pandemic, this method has a significant limitation, as the time lag from strain isolation to final dose
formulation and validation is six months. Indeed, production in eggs is a relatively slow process
and production yields are both unpredictable and highly variable from strain to strain. In particular,
if the next influenza pandemic were to arise from an avian influenza virus, and thus reduce the
egg-laying hen population, there would be a shortage of embryonated eggs available for vaccine
manufacturing. Although the production of egg-derived vaccines will continue, new technological
developments have generated a cell-culture-based influenza vaccine and other more recent platforms,
such as synthetic influenza vaccines.
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1. Introduction
Influenza occurs globally, its annual attack rate being estimated at 20–30% in children and 5–10%
in adults. Illness can result in hospitalization and death, mainly among high-risk groups. Worldwide,
annual epidemics are estimated to cause around 3 to 5 million cases of severe illness and 250,000 to
500,000 deaths [1]. Influenza A viruses are responsible for annual epidemics and sporadic pandemics.
In one study, 99% of hospitalized cases were caused by influenza A and only 1% by influenza B [2].
Influenza epidemics occur in the northern hemisphere from October to March and in the southern
hemisphere from April to September. The Global Influenza Surveillance and Response System (GISRS)
has been performing influenza virological surveillance since 1952. Since its inception, the network
has developed and now consists of over 143 National Influenza Centers (NICs) in 113 countries,
and 6 Word Health Organization (WHO) Collaborating Centers (CCs) [3]. Together, these laboratories
process around 500,000 respiratory specimens per year in order to monitor influenza activity around
the world. The NICs send approximately 8000 of the viruses isolated to the CCs for antigenic and
genetic characterization, in order to support the selection of strains for the composition of the seasonal
influenza vaccine.
The production of an optimal influenza vaccine requires constant global influenza monitoring for
the emergence and circulation of new viruses other than those circulating in the previous season [4,5].
Most seasonal flu vaccines are hen egg-derived (Table 1) in the European Union/European Economic
Area (EU/EEA) [6]. The influenza virus is grown in the allantoic cavity of embryonated hen eggs;
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the virus is then harvested, inactivated, purified and processed [7]. With current manufacturing
capacity, 413 million doses of a trivalent influenza vaccine are produced every year for the world
population [8], and in some EU/EEA countries quadrivalent inactivated influenza vaccines are
expected to substitute the trivalent formulation over time.
Table 1. Available seasonal influenza vaccines in the EU/EEA (2015/2016 season).
Manufacturer Name of Product Vaccine Type Adjuvant Produced in Age Recommended
Abbot healthcare Trivalent: Influvac Imuvac Inactivated None Egg From 6 months
AstraZeneca
Quadrivalent: Fluenz
Tetra (Flumist
quadrivalent) Trivalent:
Fluarix Alpharix Influsplit
Live attenuated None Egg From 24 months to 17 yearsTrivalent: From 6 months
GlaxoSmithKline
Quadrivalent: Fluarix
Tetra Alpharix Tetra
Influsplit Tetra
Inactivated/split None Egg From 3 years
Novartis Trivalent: AgrippalFluvirin Fluad Inactivated/subunit
None
None
Squalene
(MF59)
Egg
From 6 years
From 4 years
From 65 years
Pfizer/CSl Australia Trivalent: Afluria Enzira Inactivated None Egg From 5 years
Sanofi Pasteur Trivalent: Vaxigrip Intanza9 µg Intanza 15µg Inactivated None Egg
From 6 months
From 18-59 years
From 60 years
Also in the US, the ordinary way that flu vaccines are made is using an egg-based manufacturing
process for trivalent and quadrivalent inactivated and live attenuated influenza vaccine (Table 2) [9].
For the 2016–2017 season from 157 to 168 million doses of injectable influenza vaccine have been
distributed in US [10].
Table 2. Available seasonal influenza vaccines in the US (2016/2017 season).
Manufacturer Name of Product Vaccine Type Adjuvant Produced in Age Recommended
GlaxoSmithKline Quadrivalent: Fluarix Inactivated/split None Egg From 3 years
ID Biomedical Corp. of
Quebec (distributed by
GlaxoSmithKline)
Quadrivalent: FluLaval Inactivated/split None Egg From 3 years
Sanofi Pasteur
Quadrivalent: Fluzone
Quadrivalent: Fluzone
Intradermal Trivalent:
Fluzone high dose
Inactivated/split
Inactivated/split/intradermal
Inactivated/split
None Egg
From 6 through 35 months
From 36 through 8 years
From 9 years
From 18 through 64 years
From 65 years
Seqirus Trivalent: AfluriaFluvirin Fluad
Inactivated/subunit
Inactivated/subunit/adjuvanted None Yes Egg
From 5 through 8 years
From 4 years
From 65 years
MedImmune Quadrivalent: FluMist Live/attenuated None Egg From 2 through 49 years
Today, three parallel approaches for producing influenza vaccines are attracting the interest of
many vaccine manufacturing companies; the first and oldest is the conventional egg-derived influenza
vaccine, the second is a cell culture-derived influenza vaccine, and the third and most recent technology
is the production of synthetic vaccines (Figure 1).
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was established from the kidney of a healthy cocker spaniel by SH Madin and NB Darby at the 
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to grow under serum-free conditions [15], and MDCK cells have been used to isolate a wide variety 
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and there is a more controlled production process involving closed-system bioreactors. Moreover, 
viruses propagated in mammalian-derived tissue culture remain antigenically unchanged, unlike the 
case of incubation in embryonated eggs, because this host system induces a selection of variants that 
grow well [17]. On 1 June 2007, Optaflu, a MDCK cell culture-derived seasonal influenza vaccine was 
manufactured by Novartis Vaccines and approved by the European Medicines Agency (EMA) for 
intramuscular use in the EU [18]. It took five years before Novartis Vaccines could market Optaflu. 
Indeed, the first clinical trials had begun in Germany in 2002 with a Phase I study involving 40 
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In November 2012, the Food and Drug Administration (FDA) approved the first cell culture-
derived influenza vaccine, Flucelvax. As the original brand name of this product, Optaflu, was 
deemed unacceptable by the Center for Biologics Evaluation and Research (CBER) in the US, the 
name “Flucelvax” was proposed and accepted [21]. 
German regulatory authorities approved Celtura (Novartis), an MF59-adjuvanted, MDCK-CCIV 
A/H1N1, cell culture-derived pandemic vaccine, in November 2009. A phase I, randomized study of 
Celtura from July to September 2009 showed an antibody response plausibly associated with 
protection after the administration of a single dose [22]. A post-licensure vaccine surveillance study 
conducted in 2012 confirmed the good safety profile of Celtura (Table 3) [23]. 
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2. Cell Culture-Derived Vaccines and Vaccine Candidates
In 1995, the WHO recommended developing an alternative influenza virus cultivation system
and investigating mammalian cell culture lines [12]. Three cell lines were commercially proposed for
cell culture-derived influenza vaccines: Madin Darby canine kidney cells (MDCK), Vero cells (Kidney
epithelial cells from an African green monkey), used for more than twenty years for polio vaccine
production [13], and PER.C6, a human retina-derived cell line.
MDCK cells and Vero cells were shown to be especially promising cell-line candidates because,
at that time, influenza vaccines were produced only in embryonated hen eggs, and therefore, required
large numbers of high-quality fertile hen eggs, which could only be obtained by careful advance
planning. In the case of a pandemic strain, sufficient quantities of hen eggs may not be readily
available to produce specific vaccines because the timeline from strain identification to vaccine is
about four-six months [8], and between one to two eggs are usually required to produce one influenza
vaccine dose. Growing the influenza virus in the egg can lead to adaptations in which different
phenotypes from the wild virus circulating in humans are selected, thus egg based vaccines could
possibly be contraindicated for people with allergies to egg components [14]. The MDCK cell line
was established from the kidney of a healthy cocker spaniel by SH Madin and NB Darby at the
University of California, Berkeley, in 1958. The MDCK 33016 suspension cell line has been adapted
to grow under serum-free conditions [15], and MDCK cells have been used to isolate a wide variety
of human influenza viruses [16]. The production of cell culture-derived influenza vaccines has many
advantages. Firstly, the long lead times required by egg-based production systems are eliminated,
and there is a more controlled production process involving closed-system bioreactors. Moreover,
viruses propagated in mammalian-derived tissue culture remain antigenically unchanged, unlike the
case of incubation in embryonated eggs, because this host system induces a selection of variants that
grow well [17]. On 1 June 2007, Optaflu, a MDCK cell culture-derived seasonal influenza vaccine
was manufactured by Novartis Vaccines and approved by the European Medicines Agency (EMA)
for intramuscular use in the EU [18]. It took five years before Novartis Vaccines could market
Optaflu. Indeed, the first clinical trials had begun in Germany in 2002 with a Phase I study involving
40 volunteers aged 18–40 years; this was followed in 2003 by a Phase II study involving 200 volunteers
aged 18–60 years, and by Phase III, studies in the subsequent years up to post-marketing studies [19,20].
In November 2012, the Food and Drug Administration (FDA) approved the first cell
culture-derived influenza vaccine, Flucelvax. As the original brand name of this product, Optaflu,
was deemed unacceptable by the Center for Biologics Evaluation and Research (CBER) in the US,
the name “Flucelvax” was proposed and accepted [21].
German regulatory authorities approved Celtura (Novartis), an F59-adjuvanted, DCK-CCIV
A/H1N1, cell culture-derived pandemic vaccine, in November 2009. A phase I, randomized study of
Celtura from July to September 2009 showed an antibody response plausibly associated with protection
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after the administration of a single dose [22]. A post-licensure vaccine surveillance study conducted in
2012 confirmed the good safety profile of Celtura (Table 3) [23].
By 1998, Baxter Vaccines had already developed a Vero cell-based process to produce a new vaccine
derived from cell culture [7]. This new line of research, a Vero cell-derived pandemic vaccine based on
a wild-type A/California/2009 H1N1 strain, allowed Baxter to license in Europe. European regulatory
authorities approved this vaccine, Celvapan, in October 2009 [24]. Preflucel, also manufactured by
Baxter, is a seasonal influenza vaccine based on a Vero cell-line platform to produce three inactivated
influenza viruses, including the A/H1N1 pandemic strain. During the 2008–2009 influenza season,
a Phase III clinical study of Preflucel was conducted in the US. This demonstrated that a Vero-derived
vaccine was safe and well tolerated in both youths and adults [25,26]. However, on 20 October 2011,
the EMA was informed by the Austrian Medicines Regulatory Agency that Baxter had recalled large
batches from the EU market owing to increasing suspicion of side effects; as a precautionary measure,
the EMA then recalled all batches from European markets (Table 3) [27]. PER.C6 cell lines have been
shown to meet both EU and US regulatory requirements for the production of influenza vaccines.
Having obtained a license to use PER.C6 for influenza vaccine production, Sanofi Pasteur started
a Phase I clinical trial of their H7N1 vaccine in 2009 (Table 4). This was the first study conducted
on a cell-based H7 pandemic virus vaccine candidate, and, although the vaccine was well tolerated,
the results showed poor immunogenicity and humoral immune responses; thus, the vaccine did
not meet the criteria for vaccine approval of the Committee for Medicinal Products for Human use
(CHMP) [28]. To date, no flu vaccines derived from PER.C6 have been approved for use in humans
(Table 5).
Table 3. Summary information on published Clinical Trial of Madin Darby canine kidney (MDCK) cell
culture-derived influenza vaccine, Novartis.
Vaccine Year of Study Data Phase Trial Participants Results: Immunogenicity
Optaflu 2002
I and II, randomized,
observer-blind, controlled,
single-center
240 healthy adults aged
18–40 years and 120
elderly aged > 61 years
Both Optaflu and control vaccine met
all CHMP criteria in
hemagglutination inhibition assay
Optaflu 2004–2005
III, randomized,
observer-blind, controlled,
multicenter
1300 healthy adults aged
18–40 years and 1354
elderly aged > 61 years
Both Optaflu and control vaccine met
all CHMP criteria.
Optaflu 2005–2006
III, randomized,
observer-blind, controlled,
multicenter, lot-to-lot
variability
1200 healthy adults aged
18–40 years
Both Optaflu lots and control vaccine
met all three CHMP criteria
Celtura 2009 I, single center 176 adults Satisfactory immune responses
Table 4. Summary information on published Clinical Trial of Vero cell culture-derived influenza
vaccine, Baxter.
Vaccine Year of Study Data Phase Trial Participants Results: Immunogenicity
Celvapan 2009 I and II, prospective, randomized,open label, multicentre 200 adults and 200 elderly
Vaccine met criteria for
immunogenicity responses
Preflucel 2008-2009 III, multicenter, randomized,double-blind, 7250 adults, 3210 older
Vaccine met criteria for
immunogenicity responses
Table 5. Summary information on published Clinical Trial of PER.C6 cell culture-derived influenza
vaccine, Sanofi Pasteur.
Vaccine Year of Study Data Phase Trial Participants Results: Immunogenicity
n/a 2009 I, randomized, open label 60 adults Poor immunogenicity andhumoral immune responses
Vaccines 2017, 5, 18 5 of 8
3. New Technologies for New Influenza Vaccines
Cell production of the influenza vaccine has some limitations; several companies currently use the
MDCK and the Vero-adherent cell line although scale-up is the biggest challenge. Other non-adherent
cell lines used for the production of influenza vaccines such as PER.C6 have yielded unsuccessful results
in their first clinical studies concerning the immune response of the vaccine. The live Influenza virus
needs inactivation and/or attenuation throughout different steps of biocontainment, and consequently
produces a low yield of the final product, which represents a major limitation for this technology [29].
To attempt to overcome the limitations of cell culture vaccine production, such as the need to
propagate the virus in cells, or possible cell culture contamination, new influenza vaccines have been
produced by means of a baculovirus expression vector system (BEVS) instead of cell-line culture.
In this process, the Hemagglutinin (HA) gene sequence is inserted into an insect cell containing
a baculovirus. The insect cells are grown to modest density in an animal-free suspension culture
serum [30]. In the vaccine composition, the hemagglutinin is 45 µg for each viral strain than 15 µg of
other seasonal vaccines [31]. On 16 January 2013, the FDA approved Flublok, the first licensed vaccine
using an insect virus expression system, produced by Protein Sciences Corporation. Other influenza
vaccines are being developed by means of new technologies, especially pandemic influenza vaccines.
A Phase I study in healthy adults has demonstrated the safety and immunogenicity of a plant-produced
recombinant hemagglutinin influenza vaccine derived from the A/H1N1 pandemic strain. Specifically,
infecting the tobacco plant Nicotiana benthamiana with a hybrid vector containing the specific viral HA
allows large-scale production of a recombinant hemagglutinin protein [32]. The first study conducted
in humans assessed the immunogenicity of HAC1, a plant-produced recombinant HA influenza
vaccine [33]. Several viruses are used as recombinant vector vaccines; for example, a modified vaccinia
virus Ankara (MVA) has been used as a vaccine vehicle of the foreign HA gene of the H5N1 influenza
virus [34]. A recent phase I-II study involving 80 volunteers aged 18–29 years has demonstrated
the tolerability and immunogenicity of this vaccine. However, its immunogenicity has not yet been
compared with that of conventional H5N1 inactivated vaccines [35]. An alternative formulation
for influenza vaccines involves the use of a DNA-encoding influenza virus nucleoprotein, which is
administered through intramuscular injection. DNA nucleoprotein injection in mice induces protection
against homologous and heterologous virus strains [36]. Another strategy is the use of a chimeric
HA (cHA) for to formulate a universal influenza vaccine, a method completely different from those
mentioned so far. Since the immune system always recognizes the same domain of the HA stalk,
even if the head of the various influenza viruses is different there would be a booster response to the
vaccine without needing to repeat the vaccination before each influenza season. With this innovative
technique, all kinds of influenza vaccines could be produced, like inactivated whole vaccines, split,
live attenuated vaccines, recombinant vaccine, and DNA vaccines.
It has also been observed in the laboratory that when the immunodominant globular domain is
removed the antibody response to the HA stem increases [37,38].
4. Conclusions
Although several companies continue to produce subunit egg-derived vaccines, new manufacturing
platforms are being developed for new influenza vaccines.
The first influenza vaccine produced in eggs was licensed in 1945. Egg-derived and cell-derived
influenza vaccines will likely be produced and marketed in parallel in the next decade. The development
of faster and more innovative technologies will shorten waiting times in comparison with egg-based
vaccine production.
The production of vaccines by means of cell culture technologies has several advantages: Cell
culture manufacturing is cleaner and faster, which is especially important in the case of a pandemic;
the phenomenon of virus non-adaptation is avoided, and, lastly, the growing cell is controlled in
defined culture media and validated cell banks in accordance with Good Manufacturing Practice
(GMP), in contrast with the less strict requirements applied to egg-based vaccine production.
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So far, the two most successful cell lines have been the MDCK cell line and the Vero cell line,
the use of which has enabled seasonal and pandemic influenza vaccines to be manufactured and
marketed in Europe and the US.
Vaccine production in cell cultures has both advantages and a few disadvantages. A clear advantage
is that any adventitious infective agents in cell cultures can be detected and removed, while a major
disadvantage is that pre-existing facilities need to be either adapted or completely rebuilt [39]. Every step
of the influenza vaccine manufacturing process is steadily monitored because there are many possibilities
for contaminates : the presence of adventitious viruses in the original clinical isolate, oncogenic viruses in
cell cultures, production operators or raw materials [40].
New technological discoveries have led to state-of-the-art latest-generation influenza vaccines,
in which the vaccine is created without inactivating the influenza virus or using a subunit surface;
thus, many of the problems inherent in egg-based and cell-based production can be avoided. The great
advantage of synthetic vaccines is that the production process does not start with the whole virus,
from which the proteins of interest then have to be extracted; rather, the nucleotide sequence of
a glycoprotein, such as hemagglutinin HA, is artificially synthesized and inserted into a productive
context that is completely independent from the virus [41,42]. DNA vaccines may be future candidates
for human vaccination, and pre-constituted libraries of vaccine strains may be utilized in the event of
epidemics and, especially, pandemics [43].
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